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he Future of an Illusion*
ohn A. Bittl, MD, FACC
cala, Florida
wo reports (1,2) in this issue of the Journal describe the
esults of the PROTECT–TIMI-30 (Randomized Trial to
valuate the Relative Protection Against Post-Percutaneous
oronary Intervention Microvascular Dysfunction, Ischemia,
nd Inflammation Among Antiplatelet and Antithrombotic
gents–Thrombolysis In Myocardial Infarction-30) study, a
andomized trial whose primary outcome was unexpected.
esults in science are hard to accept when they threaten
stablished treatments (3) or violate dogma (4). How can the
esults of the PROTECT–TIMI-30 trial be put into per-
pective?
ackground. The PROTECT–TIMI-30 trial (1) was
ponsored by the manufacturer of Integrilin (eptifibatide) to
xplicate the results of REPLACE-2 (Randomized Evalu-
tion in PCI Linking Angiomax to Reduced Clinical
vents) (5), a trial sponsored by the manufacturer of
ngiomax (bivalirudin). The REPLACE-2 results sug-
ested that bivalirudin monotherapy was not inferior to the
ombination of heparin and platelet glycoprotein (GP)
Ib/IIIa blockade during PCI (5).
See pages 2364 and 2374
The PROTECT–TIMI-30 investigators (1) randomized
atients into three treatment groups: 1) bivalirudin mono-
herapy; 2) eptifibatide plus unfractionated heparin; and 3)
ptifibatide plus enoxaparin. The primary aim was to show
hat coronary flow reserve after percutaneous coronary
ntervention (PCI) would be 20% lower after the use of the
irect thrombin inhibitor than after GP IIb/IIIa blockade,
nd the primary safety objective was to show that bleeding
ifferences among the treatment groups could be minimized
y using reduced-bolus heparin or enoxaparin. Treatment
sing bivalirudin produced higher coronary flow reserves
1.43 vs. 1.33, p  0.036) than the eptifibatide combina-
ions and was associated with lower transfusion rates (0.4 %
s. 4.4%, p  0.001). Were the surprising results of the
ROTECT–TIMI-30 trial real observations or merely bad
uck?
rimary end point. Coronary flow reserve refers to the
aximum capacity of the coronary vascular bed to increase
ts flow in response to a pharmacologic-induced demand.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From Ocala Heart Institute, Munroe Regional Medical Center, Ocala, Florida.o
r. Bittl has been an investigator in clinical trials evaluating bivalirudin and
ptifibatide but has no industry relations or financial disclosures to report.he measurement is defined by the ratio of maximal
oronary flow to basal flow (6). Normal values for coronary
ow reserve commonly exceed 3.0. Values of 2.0 or greater
re used as the cutoff for selecting or deferring stenoses for
CI (7,8). Lesions of more than 50% to 70% diameter
tenosis may reduce maximal coronary flow, but stenoses
f more than 85% are required to reduce basal coronary
ow (9).
Conventional methods for measuring coronary flow re-
erve include Doppler-velocity, positron emission, or ther-
odilution techniques. In the PROTECT–TIMI-30 trial
1), coronary flow reserve was measured with an angio-
raphic method, also called the frame count reserve, that
as based on seminal observations by the authors (10) and
orrelated against Doppler-derived coronary velocity reserve
easurements in humans (11,12). The lack of a 1:1 relation
n regression analyses (12) might explain that a value of 1.4
easured as frame count reserve is equivalent to a value of
.2 measured as coronary velocity reserve using Doppler
ethods (coronary velocity reserve  0.5  frame count
eserve  1.5).
icrocirculation. Coronary flow reserve integrates two
spects of perfusion: epicardial flow and distal microvascular
esistance. In the absence of a coronary stenosis, coronary
ow reserve is a measure of microvascular function (13).
ecause the technical management of the epicardial steno-
es in the PROTECT–TIMI-30 trial (1) was ostensibly
quivalent for the treatment groups, it is reasonable to
ostulate that measurements of coronary flow reserve re-
ected differences in microvascular flow between the biva-
irudin and eptifibatide groups.
Diabetes reduces coronary flow reserve (14). The signif-
cantly higher incidence of diabetes in the bivalirudin group
han in the eptifibatide groups (44.4% vs. 36.4%) did not
nterfere with the therapeutic advantage of the direct
hrombin inhibitor. The bivalirudin-treated patients were
ess likely, however, to achieve Thrombolysis In Myocardial
nfarction (TIMI) myocardial perfusion grade 3 than the
ptifibatide-treated patients (50.9% vs. 57.9%; p  0.048),
ut the primary end point of coronary flow reserve still
avored bivalirudin treatment.
Observations from previous studies evaluating the effect
f GP IIb/IIIa blockade on microcirculatory flow do not
larify the findings of the PROTECT–TIMI-30 trial (1).
n one study of 200 patients undergoing PCI (15), those
andomized to abciximab had greater coronary flow velocity
han patients randomized to placebo. In contrast, patients in
ADILLAC (Controlled Abciximab and Device Investi-
ation to Lower Late Angioplasty Complications) (16) trial
ssigned to abciximab had a similar incidence (17.3% vs.
7.6%) of a normal myocardial blush grade after the
rocedure as those assigned to the placebo.
In the PROTECT–TIMI-30 trial (1), concomitant treat-
ent with clopidogrel may have reduced the theoretical benefitf GP IIb/IIIa inhibitor therapy (17). The finding that
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June 20, 2006:2380–3 Editorial Commentoronary flow reserve was better in the bivalirudin group may
e explained by the effect of the drug on platelets or the
eaker-than-expected effect of eptifibatide on the coronary
icrovascular response. It must be conceded, however, that
linical trials produce only general principles about treatment
egimens (18). The human intellect is almost limitless in its
bility to generate post-hoc theories about observations, but
efined pathophysiologic details of treatment effects are difficult
o obtain in multicenter clinical trials.
profusion of end points. The main objective of any
linical trial is to answer the primary question. In the
ROTECT–TIMI-30 trial (1), the measurement of the
rimary end point supported the alternative hypothesis of
ivalirudin superiority and rejected the null hypothesis as
ell as the primary hypothesis of eptifibatide superiority.
Additional insights about treatment differences might
e gleaned from the more than 30 secondary end points in
he PROTECT–TIMI-30 trial, but certain caveats exist.
he number of additional comparisons in the study ex-
eeded the median number of six comparisons per clinical
rial previously reported (19). Secondary analyses might be
nteresting, exploratory or hypothesis-generating, but they
hould be put into proper perspective (20). When many
econdary comparisons are made, the likelihood is high that
p value of 0.05 will reflect a “false-positive” result.
pplication of Bayes’ theorem shows that if the prior
robability of an effect is 10%, a p value of 0.05 from a study
ith 80% power results in a “false-positive” probability of
6% (21).
Secondary end points listed in the protocol for the
ROTECT–TIMI-30 trial included death and myocardial
nfarction (MI) within 48 h; the composite of death, MI,
nd occurrence of any ischemia on Holter within 48 h;
eath within 48 h; MI within 48 h; TIMI major hemor-
hage within 48 h; major and minor TIMI bleeding; stroke;
ntracranial hemorrhage; and thrombocytopenia. Other pre-
pecified end points included total duration of ischemia
hrough 72 h; TIMI myocardial frame count; growth of
lush; growth of blush brightness; rise in soluble CD 40
igand and RANTES levels (i.e., regulated upon activation,
ormal T-cell expressed and secreted); peak troponin level;
ncrease in the level of C-reactive protein; rates of TIMI
ow grade 3 and/or TIMI flow grade 2/3; corrected TIMI
rame count; TIMI myocardial flow reserve (TIMI myocar-
ial frame count) before and after PCI; digital subtraction
ngiography flow reserve; thrombus burden after PCI;
ide-branch occlusion after PCI; an increase in the levels of
nterleukin-1 and -6; and fragment F1.2 levels. Other
tatistical provisions were made for adjustments for admis-
ion troponin level; normality or non-normality of data
llowing transformation; and duration of clopidogrel pre-
reatment. In addition to the prespecified end points and
djustments in the protocol, the study listed other secondary
nalyses and statistical adjustments, such as any increase in
reatine kinase-myocardial band from a normal baseline,
re-PCI TIMI myocardial perfusion grade; stent type; bre-PCI corrected TIMI frame count; diabetes; previous
oronary artery disease; location of lesion; previous aspirin
se; age; and previous PCI.
In the PROTECT–TIMI-30 trial (1), the clinical end
oint of death or MI did not differ between the treatment
roups. No differences in biomarker levels between
ivalirudin-treated and eptifibatide-treated patients were
bserved.
nexpected bleeding results. The primary safety end
oint of TIMI major bleeding in the PROTECT–
IMI-30 trial (1) was statistically similar between the
ivalirudin and eptifibatide groups (0.0% vs. 0.7%; p 
.31), which is not surprising, because the occurrence of
IMI major bleeding is so infrequent after PCI that it not
discriminating end point to define treatment safety. The
aboratory component of TIMI major bleeding reflects
ear-catastrophic blood loss. The clinical component of
IMI major bleeding is intracranial hemorrhage, an end
oint that has guided fibrinolytic practice and trial design
22–24) but occurs 10 times less frequently after high-risk
CI than after fibrinolytic therapy (25). End points in
linical trials should be clinically meaningful (3). Transfu-
ions, vessel repair, and retroperitoneal hemorrhage have
een the more important clinical events that define safety
ifferences among treatments in PCI trials.
An unexpected safety finding in the PROTECT–
IMI-30 trial (1) was the 10-fold higher rate of transfu-
ions in the eptifibatide-treated patients with reduced-bolus
eparin (4.0%) or enoxaparin (4.6%) than in the bivalirudin-
reated patients (0.4%), despite activated clotting time
ACT) values that were 75 s higher in the bivalirudin group
han in the heparin group. The effect of postprocedural
leeding on long-term outcome after PCI recently has been
mphasized. In the REPLACE-2 trial (26), postprocedural
leeding was more strongly correlated with one-year mor-
ality (odds ratio, 3.5; 95% confidence interval 1.9 to 6.5)
han was elevation of creatine kinase-myocardial band
nzyme (odds ratio, 2.6; 95% confidence interval 1.5 to 4.5).
enal risks. A substudy (2) of the PROTECT–TIMI-30
rial was conducted to identify correlates of bleeding. The
ivalirudin group was eliminated from the analysis. The
verall incidence of major or minor bleeding within 48 h of
CI in the two eptifibatide groups treated with heparin and
noxaparin was 3.2%. All four major bleeds occurred in
noxaparin-treated patients. Although reduced eptifibatide
nfusions have been recommended when the creatinine
learance is 50 ml/min, 15 of 33 patients (45%) nonethe-
ess received the full dose. The overdosage was associated
ith an increased risk of bleeding (9.1%).
On univariate analysis, the risk of bleeding was related to
ge and estimates of creatinine clearance but not to creati-
ine itself. On multivariate testing, bleeding risk was related
o patient age and surprisingly not to estimates of creatinine
learance or to creatinine measurements (2). The lack of
orrelation between bleeding risk and renal function has not
een found in other contemporary studies (27) and raises
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Editorial Comment June 20, 2006:2380–3tatistical concerns. Conclusions made from well-conducted
ultivariate analyses are unambiguous when all the inde-
endent variables (e.g., age and creatinine clearance) are
tatistically independent of each other. Because creatinine
learance was not measured directly but was calculated from
he Cockgroft-Gault formula in the PROTECT–TIMI-30
rial (2), an equation that contains the term (140  age),
edundant information inserted into the multivariate model
ay be a source of multicollinearity. This may lead to unrea-
onable coefficients for variables, inflated standard errors, or
igns different from the expected results in multivariate models.
ulticollinearity may thus lead to erroneous elimination of
ariables that otherwise are otherwise related to outcomes (28).
The authors emphasized the importance of reduced dosing
f GP IIb/IIIa blockers in patients with advanced age or renal
mpairment, but they should reconsider bivalirudin as an
lternative associated with greater absolute treatment benefit in
atients with impaired renal function than in those with
ormal renal function (29).
ctivated clotting time (ACT) fallacies. The counterin-
uitive relation between transfusions and ACT was more
ronounced in the PROTECT–TIMI-30 trial (1,2) than it
as in the REPLACE-2 trial (5). If the bivalirudin patients
ad been included in the multivariate model for bleeding in
he PROTECT–TIMI-30 trial (2), increased rates of
leeding might have been associated with lower ACT
alues.
Several studies have questioned the ability of ACT
easurements to predict bleeding or ischemic complications
n contemporary PCI practice. No relation between bleeding
nd ACT measurements was observed in the PROTECT–
IMI-30 trial (1,2), the REPLACE-2 trial (5), or in a
eta-analysis of several other randomized trials performed
ver the course of a decade (30). Repeat measurements of
CTs have a high coefficient of variation (31) and might
imply document qualitatively whether or not an anticoagulant
as been given (32).
ynthesis. Scientific knowledge from clinical trials is ten-
ative (33). Concerns about end points, concomitant med-
cations, bias, or chance influence the veracity of trial results
nd their ability to change clinical practice. Resistance to
hange is great when results threaten a company’s product
3), contradict the beliefs of the investigators, or run
ontrary to the wishful thinking that underlies all human
ndeavors (4).
The authors of the PROTECT–TIMI-30 trial (1) and
ditors have squarely reported the unexpected outcome
or the primary end point of coronary flow reserve,
liminated excessive claims based on secondary end
oints, and concluded that bivalirudin monotherapy was
t least physiologically equivalent to and safer than the
ptifibatide combinations.
The report of the PROTECT–TIMI-30 trial (1) will
ikely have a polemic effect in clinical practice. Users of
ivalirudin will defend their choice by pointing to reduced
leeding and the theoretical advantage of improved coro-ary flow reserve. Users of eptifibatide will emphasize the
rends in secondary end points. Any remaining users of
noxaparin will wish for an improved safety profile and
ower bleeding. The forthcoming publication of the
CUITY (Catheterization and Urgent Intervention Triage
trategy) trial, another industry-sponsored trial comparing
ivalirudin with enoxaparin during PCI, will generate more
rovisional results to challenge existing illusions about
arginal superiority of one treatment over another.
eprint requests and correspondence: Dr. John A. Bittl, 13013
ighway 475, Ocala, Florida 34480. E-mail: jabittl@aol.com.
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